322 related articles for article (PubMed ID: 21434940)
1. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
2. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
[TBL] [Abstract][Full Text] [Related]
3. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
4. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE; Girolomoni G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
6. Novel biologic therapies in development targeting IL-12/IL-23.
van de Kerkhof PC
J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
[TBL] [Abstract][Full Text] [Related]
7. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab.
Luo J; Wu SJ; Lacy ER; Orlovsky Y; Baker A; Teplyakov A; Obmolova G; Heavner GA; Richter HT; Benson J
J Mol Biol; 2010 Oct; 402(5):797-812. PubMed ID: 20691190
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab poised to enter the psoriasis market.
Schmidt C
Nat Biotechnol; 2008 Dec; 26(12):1317-8. PubMed ID: 19060851
[No Abstract] [Full Text] [Related]
12. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
13. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
[TBL] [Abstract][Full Text] [Related]
14. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
[TBL] [Abstract][Full Text] [Related]
15. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
16. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
Bartlett BL; Moody MN; Tyring SK
Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
Zaghi D; Krueger GG; Callis Duffin K
J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
